Emcure Pharmaceuticals Ltd (EMCURE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Emcure Pharmaceuticals Ltd (EMCURE) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.56 Billion ≈ $27.71 Million USD) by net assets (Rs48.84 Billion ≈ $528.19 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See EMCURE equity financing ratio to measure how much of total assets are equity-financed.
Emcure Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2022–2026)
This chart illustrates how Emcure Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Emcure Pharmaceuticals Ltd to evaluate the quality of earnings relative to operating cash generation.
Emcure Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Emcure Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Americold Realty Trust
NYSE:COLD
|
0.014x |
|
Steadfast Group Ltd
AU:SDF
|
0.076x |
|
Marex Group plc Ordinary Shares
NASDAQ:MRX
|
-0.206x |
|
Changsha Jingjia Microelectronics Co Ltd
SHE:300474
|
-0.013x |
|
Sunrise Communications AG
NASDAQ:SNRE
|
0.071x |
|
OPENLANE, Inc.
NYSE:OPLN
|
0.103x |
|
Corporación Moctezuma S.A.B. de C.V
MX:CMOCTEZ
|
0.102x |
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
-0.168x |
Annual Cash Flow Conversion Efficiency for Emcure Pharmaceuticals Ltd (2022–2026)
The table below shows the annual cash flow conversion efficiency of Emcure Pharmaceuticals Ltd from 2022 to 2026. For the full company profile with market capitalisation and key ratios, see market cap of Emcure Pharmaceuticals Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs49.77 Billion ≈ $538.21 Million |
Rs8.51 Billion ≈ $91.98 Million |
0.171x | -6.86% |
| 2025-03-31 | Rs46.42 Billion ≈ $501.97 Million |
Rs8.52 Billion ≈ $92.11 Million |
0.183x | -47.79% |
| 2024-03-31 | Rs31.22 Billion ≈ $337.61 Million |
Rs10.97 Billion ≈ $118.66 Million |
0.351x | +24.70% |
| 2023-03-31 | Rs26.50 Billion ≈ $286.55 Million |
Rs7.47 Billion ≈ $80.77 Million |
0.282x | -22.43% |
| 2022-03-31 | Rs21.14 Billion ≈ $228.64 Million |
Rs7.68 Billion ≈ $83.08 Million |
0.363x | -- |
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more